Brokerages Set Monopar Therapeutics Inc. (NASDAQ:MNPR) Price Target at $107.00

Monopar Therapeutics Inc. (NASDAQ:MNPR) has earned an average recommendation of “Buy” from the thirteen ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $107.00.

Several equities analysts recently commented on MNPR shares. BTIG Research restated a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Leerink Partners assumed coverage on Monopar Therapeutics in a report on Monday, November 10th. They set an “outperform” rating and a $115.00 price objective for the company. Raymond James Financial downgraded shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and reduced their target price for the company from $142.00 to $123.00 in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a report on Thursday, January 29th.

Insider Activity

In other Monopar Therapeutics news, CFO Quan Anh Vu bought 1,500 shares of Monopar Therapeutics stock in a transaction dated Friday, December 26th. The shares were acquired at an average cost of $69.95 per share, with a total value of $104,925.00. Following the acquisition, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at $104,925. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics in the fourth quarter worth $188,000. Virtu Financial LLC bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at about $654,000. Invesco Ltd. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $219,000. ADAR1 Capital Management LLC lifted its position in Monopar Therapeutics by 79.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock worth $15,274,000 after buying an additional 103,909 shares in the last quarter. Finally, Virtus Investment Advisers LLC bought a new stake in Monopar Therapeutics during the 4th quarter worth about $233,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Stock Up 7.0%

NASDAQ:MNPR opened at $55.49 on Friday. The firm has a market capitalization of $370.67 million, a PE ratio of -16.13 and a beta of 1.58. Monopar Therapeutics has a 12-month low of $26.06 and a 12-month high of $105.00. The firm has a 50-day moving average price of $62.54 and a 200 day moving average price of $68.16.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.